162 related articles for article (PubMed ID: 17276069)
1. Targeting malignant glioma survival signalling to improve clinical outcomes.
Wong ML; Kaye AH; Hovens CM
J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
[TBL] [Abstract][Full Text] [Related]
2. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors in children with malignant gliomas.
Herrington B; Kieran MW
Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies for malignant glioma.
Lukas RV; Boire A; Nicholas MK
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S29-36. PubMed ID: 18076315
[TBL] [Abstract][Full Text] [Related]
7. Cell surface receptors in malignant glioma.
Li YM; Hall WA
Neurosurgery; 2011 Oct; 69(4):980-94; discussion 994. PubMed ID: 21522029
[TBL] [Abstract][Full Text] [Related]
8. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.
Newton HB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):595-614. PubMed ID: 14599084
[TBL] [Abstract][Full Text] [Related]
9. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
He S; Dibas A; Yorio T; Prasanna G
Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy for malignant glioma.
Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
[TBL] [Abstract][Full Text] [Related]
11. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
12. STI1 promotes glioma proliferation through MAPK and PI3K pathways.
Erlich RB; Kahn SA; Lima FR; Muras AG; Martins RA; Linden R; Chiarini LB; Martins VR; Moura Neto V
Glia; 2007 Dec; 55(16):1690-8. PubMed ID: 17886292
[TBL] [Abstract][Full Text] [Related]
13. [Molecular-targeted therapy for malignant glioma].
Yamanaka R
Brain Nerve; 2009 Feb; 61(2):177-88. PubMed ID: 19235468
[TBL] [Abstract][Full Text] [Related]
14. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Ruano Y; Mollejo M; Camacho FI; Rodríguez de Lope A; Fiaño C; Ribalta T; Martínez P; Hernández-Moneo JL; Meléndez B
Cancer; 2008 Apr; 112(7):1575-84. PubMed ID: 18260157
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin.
Yin D; Kawabata H; Tcherniamtchouk O; Huynh T; Black KL; Koeffler HP
Int J Oncol; 2007 Nov; 31(5):1193-8. PubMed ID: 17912447
[TBL] [Abstract][Full Text] [Related]
16. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
Hargrave D
Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
[TBL] [Abstract][Full Text] [Related]
17. Emerging targeted treatments for malignant glioma.
Mulholland PJ; Thirlwell C; Brock CS; Newlands ES
Expert Opin Emerg Drugs; 2005 Nov; 10(4):845-54. PubMed ID: 16262566
[TBL] [Abstract][Full Text] [Related]
18. [Signal transduction by protein tyrosine kinases and antitumor agents].
Mao YJ; Li HH; Li JF; Shen JS
Yao Xue Xue Bao; 2008 Apr; 43(4):323-34. PubMed ID: 18664191
[TBL] [Abstract][Full Text] [Related]
19. delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation.
Heiss A; Ammer H; Eisinger DA
Exp Cell Res; 2009 Jul; 315(12):2115-25. PubMed ID: 19362548
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
